Cigna Medical Coverage Policy

Subject: Pulsed Electromagnetic Therapy

Effective Date: 11/15/2016
Next Review Date: 11/15/2017
Coverage Policy Number: 0236

Table of Contents
Coverage Policy .................................................. 1
General Background ........................................... 1
Coding/Billing Information ................................... 5
References .......................................................... 6

Related Coverage Resources
Negative-Pressure Wound Therapy/Vacuum-Assisted Closure (VAC) for Nonhealing Wounds
Tissue-Engineered Skin Substitutes

INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna companies. Coverage Policies are intended to provide guidance in interpreting certain standard Cigna benefit plans. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Proprietary information of Cigna. Copyright ©2016 Cigna

Coverage Policy
Cigna does not cover pulsed electromagnetic therapy (e.g., Diapulse®, SofPulse®, Provant® Wound Closure System) for any indication, including wound care management, because it is considered experimental, investigational or unproven.

General Background
Electromagnetic therapy, often termed pulsed electromagnetic field (PEMF), has been proposed as a treatment for various conditions. Although similar to electrical stimulation, electromagnetic therapy uses an electromagnet to generate electrical current and uses nonthermal pulsed electromagnetic energy to deliver the current. This modality of treatment has been shown to induce various responses (e.g., increased blood flow, collagen formation, granulocyte infiltration) in both in vitro and animal models, primarily to induce wound healing (Blue Cross and Blue Shield Association Technology Evaluation Center [BCBSA TEC], 2005).

In contrast to electrical stimulation, electromagnetic therapy does not involve the use of current, leads, or electrodes. Pulsed electromagnetic devices that are used for wound therapy utilize generators designed to create radiofrequency signals that are typically delivered through coils which do not directly contact the skin. In relation to chronic wound treatment, electromagnetic therapy primarily refers to pulsed electromagnetic fields in the radiofrequency band without thermal effects. It has been suggested that pulsed electromagnetic therapy stimulates blood flow by a rapid peristaltic mechanism on the vessel walls, rather than a heating action or by secondary vasodilatation, and promotes cell proliferation for wound healing.

Pulsed electromagnetic therapy (PEMF) has also been recommended for treatment of painful injuries or inflammation. When used for these indications evidence in the scientific literature suggests that PEMF results in
vasodilatation, modification of the inflammatory process, reduction of edema, and enhanced tissue repair. Several devices are available for management of these conditions and utilize varying frequencies, field strength, and pulse widths although there is little published data to support selection of any of these devices (Fernandez, et al., 2007). One type of electromagnetic therapy, shortwave diathermy (continuous pulsed), is often used for the treatment of pain. It uses radiofrequency electromagnetic fields for therapeutic heating of tissue. Frequency related electromagnetic stimulation (FREMS) uses a short-wave diathermy (continuous or pulsed) which heats tissues and has also been proposed for the treatment of pain.

U.S. Food and Drug Administration (FDA)
A number of devices used for electromagnetic therapy have been approved by the FDA through the 510(k) approval process. In particular when used to treat wounds the FDA considers these devices as Class III devices which require a premarket approval. Some of these devices have been cleared by the FDA more specifically as short-wave diathermy devices or radiofrequency stimulation devices (e.g., Provant Wound Closure System [Regenesis® Biomedical, Scottsdale, AZ]; Diapulse® [Diapulse Corporation of America, Great Neck, NY]; SofPulse® [Electropharmacology, Inc., Alachoa, FL]). Several of the devices are intended for the treatment of postoperative pain and edema in superficial tissue and not specifically for wound treatment. Approval for the use of these devices specifically for the treatment of chronic wounds was not found on the FDA site.

Literature Review
Wound Care Management
Studies in the published medical literature comparing electromagnetic therapy devices with established wound care management are lacking. The clinical studies evaluating the devices and clinical outcomes have been few, are limited in sample size with poorly-defined patient selection criteria, and have limited reporting of methodological details (Ravaghi, et al., 2006; Olyaee Manesh, et al., 2006; Ritz, et al., 2003). There is little consensus among authors regarding duration of treatment or technique of application. Two published Cochrane reviews assessed the effects of electromagnetic therapy on wounds, one evaluated venous leg ulcers (Ravaghi, et al., 2006; Aziz, et al., 2015 [update]) and a second evaluated the healing of pressure ulcers (Olyaee Manesh, et al., 2006; Aziz, et al., 2010 [update]). The results of both reports provide no evidence of benefit to electromagnetic therapy when used for wound healing. In addition, a systematic review (Reddy, et al., 2008) found minimal data to support therapies such as electromagnetic therapy for the treatment of pressure ulcers.

In one study, the Provant Wound Closure System was specifically evaluated. Ritz et al. (2003) published the results of a randomized trial involving 49 patients with pressure ulcers who received standard wound therapy combined with the Provant Wound Closure System. The results indicate that when compared to a placebo (modified Provant device), Stage II wounds treated with Provant healed faster (26 days versus 66 days, respectively). The authors also reported that Provant-treated wounds showed an average 87% reduction in surface area compared to a 56% reduction for placebo; however no time period was specified. Furthermore, the authors did not compare outcomes with other effective, established wound closure devices or treatments making comparisons difficult.

In an earlier publication, George et al. (2002) reported on a series of in-vitro studies that evaluated cellular mechanisms involved in cell proliferation induction (CPI). CPI theoretically employs sensation-free radiofrequency (RF) stimuli to stimulate dormant cells in damaged wound tissue, and is a technique associated with the Provant Wound Closure System. The authors confirmed that CPI-induced proliferation of fibroblasts and epithelial cells varies as a function of both the treatment dose and the duration of treatment; the author's further hypothesized CPI treatment may accelerate wound closure.

In August 2005, the BCBSA TEC (2005) reviewed the available evidence for electrical stimulation and electromagnetic therapy for chronic wounds. A total of five studies involving 155 patients were reviewed. The panel concluded that the available evidence did not convincingly demonstrate electrical stimulation or electromagnetic therapy led to significant health outcome benefits on the most important clinical outcome, (i.e., number of patients who heal completely). BCBSA TEC concluded that the evidence was not sufficient to permit conclusions regarding the efficacy of electromagnetic therapy or electrical stimulation as an adjunctive treatment for wound healing.

The results of a randomized controlled trial by Czyz et al. (2012) investigated the benefits of electromagnetic energy in eyelid wound healing using an electromagnetic energy patch (n=57) for subjects who underwent blepharoplasty. In comparison to a placebo the authors reported no difference in pain. The difference in
physician graded erythema was statistically significant in favor of the electromagnetic energy patch although the authors concluded there was no effect on postoperative pain, edema or ecchymosis. Limitations of this study included small sample size therefore results cannot be generalized to a larger population.

Kwan et al. (2015) published the results of a prospective randomized double-blind controlled trial evaluating the effectiveness of pulsed electromagnetic field (PEMF) for the treatment of diabetic foot ulcers (N=13). Subjects were allocated to either active PEMF (n=7) or inactive PEMF (n=6), for up to 14 one hour sessions over three weeks. Treatment was performed until the wound healed or until all 14 sessions were completed. Outcome measures included degree of healing after 14 treatment sessions with subsequent follow-up at one month. At the end of the treatment session, the authors reported there was an 18% decrease in ulcer size in the active PEMF group compared to 10% decrease in ulcer size in the control group. The active PEMF group also demonstrated an increase in cutaneous capillary blood flow of 28% and 14% increase in capillary diameter. The control had a decrease in both capillary blood velocity and diameter. The authors concluded the results of the study supported PEMF accelerated wound closure, decreased wound depth, and increased microcirculation. The study is limited by small sample size and by variability in sites of ulcer location of each subject (ulcers were located on different sites of the feet).

Other Indications

Evidence in the published peer-reviewed scientific literature evaluating PEMF for conditions other than wound management consists mainly of case series with few randomized controlled trials. PEMF theoretically offers some potential benefit and has been utilized for the treatment of numerous conditions, such as subacromial impingement syndrome, lateral epicondyritis, tinnitus, soft tissue injuries, multiple sclerosis, fibromyalgia, diabetic peripheral neuropathy, plantar fasciitis and for various other conditions related to pain (Ogilvie-Harris, et al., 1995; Ghossaini, et al., 2004; Uzuncu, et al., 2007; Fernandez, et al., 2007; Aktas, et al., 2007; Thomas, et al., 2007; Heden and Pilla, 2008, Ay and Evcik 2009; Subbeyaz, et al., 2010, Omar, et al., 2012; Brook, et al., 2012; Bosi, et al., 2013; Amatya, et al., 2013; Muccioli, et al., 2013; Maestu, et al., 2013; de Freitas, et al., 2014; Osti, et al., 2015). When employed for the treatment of pain, study results are mixed, some authors report no difference in pain among study groups (Aktas, et al., 2007; Fernandez, et al., 2007, Ay and Evcik, 2009) while others report improvement in various pain parameters after PEMF therapy (Uzuncu, et al., 2007; Thomas, et al., 2007; Heden and Pilla, 2008, Omar, et al., 2012; Maestu, et al., 2013; Muccioli, et al., 2013; de Freitas, et al., 2014). In some studies, despite improvement in pain, other treatment modalities were used making study interpretations and comparisons difficult (Ay and Evcik, 2009; Omar, et al., 2012).

Diabetic Neuropathy: The effects of PEMF on diabetic neuropathy have also been investigated. Wrobel, et al. (2009) published the results of a randomized placebo-controlled double blind study to determine whether low frequency magnetic field can influence pain intensity, quality of life and sleep, and glycemic control in patients with painful diabetic polyneuropathy (n=61). The authors noted that both treatment and control groups demonstrated a significant reduction in pain intensity after the first week of treatment that persisted until the end of the follow-up period (five weeks), with no significant differences between groups. Similar improvements were noted in quality of life values, with no significant differences between groups. In the authors opinion there was no advantage to low frequency pulsed electromagnetic field stimulation compared to sham therapy for the outcomes measured. Weintraub et al. (2009) reported the results of a randomized double-blind controlled trial evaluating the effects of PEMF therapy in reducing diabetic neuropathic pain, influencing sleep, and for nerve regeneration. The study group involved 225 individuals randomly assigned to receive either PEMF or sham treatment. Outcomes were measured using a visual analog score (VAS), Neuropathy Pain Score (NPS), and the Patients Global Impression of Change (PGIC). There was a trend to a reduction in the PGIC score in favor of the PEMF group, however there were no significant differences between groups in neuropathic pain intensity or VAS. PEMF was not effective in reducing diabetic neuropathic pain. Pieber et al. (2010) reviewed the evidence evaluating different types of electrotherapy for the treatment of diabetic peripheral neuropathy and noted conflicting results for pulsed and static electromagnetic therapy; some studies reported the treatment was not effective and some studies reported a short-term analgesic effect (Pieber, et al., 2010). The authors noted differences in study designs, the use of various stimulating patterns, and inconsistent outcomes made comparisons across studies difficult. Bosi et al. (2013) reported the results of a randomized trial evaluating the efficacy of FREMS as a treatment of symptomatic peripheral neuropathy in patients with diabetes mellitus. Patients (n = 110) with symptomatic neuropathy were randomized to FREMS (n = 54) or placebo (n = 56). The primary endpoint was change in nerve conduction velocity (NCV) of the deep peroneal, tibial and sural nerves; secondary endpoints included the effects of treatment on pain, tactile, thermal, and vibratory sensations. In the intention to treat group NCV results were not different between FREMS and placebo. There was a decrease in
day and night pain in the FREMS group which was significant initially but not at three months after treatment. Investigators concluded FREMS proved to be a safe treatment for symptomatic diabetic neuropathy; there no effect on NCV and a transient improvement in pain. The results of the study are limited by short term outcomes, further trials evaluating long-term outcomes are needed to support clinical efficacy.

Evidence based guidelines published by the American Academy of Neurology (Bril, et al., 2011) do not support electromagnetic field therapy as a treatment for peripheral diabetic neuropathy; after reviewing one Class I study (randomized controlled clinical trial) the authors noted electromagnetic field treatment is probably not effective for the treatment of peripheral neuropathy.

**Knee Osteoarthritis:** Authors have also investigated the effectiveness of PEMF for treatment of osteoarthritis of the knee with mixed results (Bagnato, et al., 2016; Wuschech, et al., 2015; Iannitti, et al., 2013; Negm, et al., 2013; We, et al., 2013; Dundar, et al., 2015). One recently published randomized controlled trial (n=60) suggested PEMF therapy for pain management in patients with knee osteoarthritis was effective when applied for 12 hours/day for four weeks, as evidence by reduced VAS and WOMAC scores in the short-term (one month) following PEMF therapy, however results cannot be generalized due to a small sample population and short term follow-up (Bagnato, et al., 2016). A systematic review of 14 randomized controlled trials published by We et al. (2013) provided no evidence of significant effects observed at any time point when used for pain. The authors noted however that some trials using high quality methodology showed PEMF was more effective than placebo at four and eight weeks and there was some improvement of function at eight weeks demonstrated in some trials. It was noted that three trials reviewed applied PEMF at intensity greater than recommended levels. Negm et al. (2013) published results of a systematic review and meta-analysis evaluating PEMF for treatment of knee OA which included seven randomized controlled trials. Based on the author’s conclusion low frequency PEMF improved physical function but not pain intensity.

In 2013 the American Academy of Orthopaedic Surgeons (AAOS) noted within a second edition, evidence based guideline titled “Treatment of Osteoarthritis of the Knee” (AAOS, 2013) that due to the overall inconsistent findings for various physical agents and electrotherapeutic modalities, the authors were not able to make a recommendation for or against the use of these electromagnetic technologies in patients with symptomatic osteoarthritis of the knee.

Vavken, et al (2009) published a meta-analysis evaluating the effectiveness of pulsed electromagnetic fields for the management of osteoarthritis of the knee. In all, nine randomized controlled trials were reviewed reporting on a total of 483 patients. Although there was a significant effect of PEMF six weeks after treatment in activities of daily living, there was no significant difference in pain between treatment group and controls. The authors acknowledged PEMF may be useful and effective in addition to conservative management of osteoarthritis of the knee, although future studies are needed to confirm their findings.

Evidence published in the peer-reviewed medical literature illustrates differences in field strengths and frequency, extent of application, duration and frequency of therapy. In addition reported clinical outcomes and methods used for assessment vary among author groups precluding strong evidence-based conclusions. At present the there is insufficient evidence to support clinical utility of PEMF as a treatment for osteoarthritis of the knee.

**Post-operative and Non Post-operative Pain:** Hayes published a Health Technology Brief September 2015 evaluating PEMF therapy as a treatment for postoperative knee pain and edema. Five studies were identified and reviewed evaluating safety and efficacy as a healing therapy following surgery of the knee. All five studies were randomized controlled trials; according to Hayes two were fair quality and three were poor quality. Hayes concluded due to the poor quality of evidence it is unclear if PEMF provides added benefits for decreasing pain and swelling, improving knee function and accelerating recovery following knee surgery (Hayes, 2015).

Omar et al., (2012) published the results of a randomized controlled trial (N=40) evaluating the effectiveness of PEMF as a conservative form of treatment for low back pain with radicular symptoms. The study group consisted of subjects over age 25 years with unilateral radicular pain with or without low back pain and diagnosed with lumbar disc prolapse by magnetic resonance imaging. The experimental group received standard medical treatment in addition to PEMF; the control group received standard medical treatment in addition to placebo treatment with the machine turned off. Clinical outcome measures included visual analog scale (VAS), modified Oswestry Low Back Pain Disability Questionnaire (OSW) for determining impact on
activities of daily living and somatosensory evoked potentials for dermatomes. Statistical significance was reported for both groups for VAS and OSW scores after PEMF therapy. A significant decrease of hypothesia, improvement of ankle hyporeflexia and improvement of positive straight leg-raising test between groups was reported. Adverse events were not reported and standard medical treatment was not defined. The authors concluded PEMF therapy was an effective modality for treatment of low back pain and radicular symptoms, however further research is needed involving large numbers of subjects to support recommendation as a routine conservative form of treatment.

Guo et al. (2012) reported the results of a meta-analysis evaluating clinical efficacy of PEMF related to post-operative pain, non-post-operative pain and wound healing. A total of 25 controlled trials met inclusion criteria (N=1332) for the analysis. Sixteen trials reported pain outcomes (N=936 treated with PEMF, N=962 control group) for which the authors noted a clinically and statistically significant improvement for patients receiving active treatment (PO: P < 0.0001, NPO: P < 0.0001). The authors reported that variables related to pathology, anatomy, duration of symptoms, duration of therapy, and technologies were examined for relevance to study outcome. Regarding anatomical and pathological variables, the authors concluded there wasn’t enough evidence to draw conclusions regarding efficacy for the treatment of degenerative diseases; a majority of the studies involved treatment of subjects with pain and edema arising from soft-tissue injury. For duration of therapy the response of PEMF was independent of the duration of symptoms prior to treatment. When examining device variability it was not clear whether the type of device used or the minutes of therapy were the driving factor for a positive outcome. In the author’s opinion, it was the duration of therapy overall that was the most probable predictor of clinical effectiveness.

Use Outside of the US: Pulsed electromagnetic therapy devices have been approved for use by other health authorities in countries outside the United States. The Australian Register of Therapeutic Goods (ARTG 213222), has approved PEMF as medical therapy for treatment of chronic and acute pain, blood circulation and general well-being; however, formal guidelines regarding indications for use were not found. In addition, I-One (IGEA Clinical Biophysics, Italy) has received European CE Marking approval. The device is intended for use following joint surgery and in early stages of osteoarthritis. I-One Therapy is not available in the US and is not FDA approved.

Summary
There is insufficient evidence in the published, scientific literature to support the effectiveness of pulsed electromagnetic field therapy devices (e.g., Diapulse, SofPulse, Provant Wound Closure System) for wound care management. Studies comparing these devices with established wound care management modalities are lacking and do not support improvement in net health outcomes.

Additionally, data are limited evaluating electromagnetic field therapy devices for other indications including but not limited to pain or soft tissue injuries. As a result conclusions cannot be made regarding clinical efficacy when used for these indications and clinical utility has yet to be proven.

Coding/Billing Information

Note: 1) This list of codes may not be all-inclusive.
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Experimental/Investigational/Unproven/Not Covered when used to report pulsed electromagnetic therapy (e.g., Diapulse®, SofPulse®, Provant® Wound Closure System):

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E0761</td>
<td>Non-thermal pulsed high frequency radiowaves, high peak power electromagnetic energy treatment device</td>
</tr>
<tr>
<td>E0769</td>
<td>Electrical stimulation or electromagnetic wound treatment device, not otherwise classified</td>
</tr>
<tr>
<td>G0295</td>
<td>Electromagnetic therapy, to one or more areas, for wound care other than</td>
</tr>
<tr>
<td>Coverage Policy Number: 0236</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>G0329</strong> Electromagnetic therapy, to one or more areas for chronic stage III and stage IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care</td>
<td></td>
</tr>
</tbody>
</table>


**References**


13. Blue Cross and Blue Shield Association (BCBSA). Technology Evaluation Center (TEC). Electrical stimulation or electromagnetic therapy as adjunctive treatments for chronic skin wounds. (TEC).


